Phase II
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.
It was a relatively quiet week for clinical trial news. Here’s a look.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Following approval of its coronavirus vaccine, the first in the world, Russia plans to initiate a new study involving 40,000 people as the country looks to boost production and distribute the drug to patients in that country, as well as to patients in countries it has struck deals with.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
PRESS RELEASES